Other languages Opthea Limited

Equities

Market Closed - Australian S.E. Other stock markets 02:10:11 2024-05-03 am EDT			5-day change	1st Jan Change
0.615 ^AUD	+0.82%		-8.89%	+7.89%

Apr. 03	Opthea Limited Announces Board Changes	CI
Feb. 29	Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	MT

Opthea Limited Announces Board Changes	Apr. 03
Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	Feb. 28
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28
Opthea Appoints Chief Medical Advisor; Shares Decline 4%	Feb. 19
Opthea Appoints Arshad M. Khanani as Chief Medical Advisor	Feb. 19
Opthea Concludes Enrollment in Inaugural Wet AMD Drug Trial	Feb. 14
Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept	Feb. 14
Opthea Makes Management Appointments As Part of Next Stage Drug Trial; Shares Up 13%	Feb. 01
Opthea to Receive Remaining Committed Funds, Additional Financing for Sozinibercept Trials; Shares Up Pre-Bell	Dec. 27
Traders Look Ahead to Flat Day After Post-Christmas Rally	Dec. 27
Top Premarket Gainers	Dec. 27
Opthea Secures $85 Million for Advancing Clinical Trials, Pre-Commercialization Activities	Dec. 27
Opthea Receives AU$9 Million Tax Rebate for Fiscal Year 2023	Dec. 19
Opthea Limited Announces Transition of Megan Baldwin to Founder and Chief Innovation Officer, Effective October 27, 2023	23-10-26
Opthea Limited Announces Executive Changes	23-10-26
Opthea Completes Retail Entitlement Offer; Shares Fall 3%	23-09-20
Opthea's Options Suspended from Quotation on ASX; Shares Rise 3%	23-09-14
Opthea Opens AU$16 Million Retail Entitlement Offer	23-08-30
Opthea Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30
Top Midday Decliners	23-08-28

No results for this search